Navigation Links
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint

ulation and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for PMD.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing drugs for treating severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is in Phase 3 clinical trials for treating the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For more information, please visit www.corcept.com.

Forward-looking Statements

Statements made in this news release – other than statements of historical fact – are forward-looking statements. These include information relating to Corcept’s PMD clinical development program and the timing of the completion of Phase 3 trials. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied here. For example, there can be no assurances on the efficacy, safety, enrollment completion or success of clinical trials; the regulatory process or regulatory approvals; commercial success; in addition, trial timetables may not be accurate. Risk factors are explained in the company's SEC filings, all of which are available from its Web site (www.corcept.com) or from the SEC's Web site (www.sec.gov). The company does not have any intention or duty to update forward-looking statements made in this news release.


CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270





Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Saturday 30 August 2014: The first comprehensive ESC ... presented at ESC Congress 2014 by Task Force Chairpersons ... , The "2014 ESC Guidelines on the diagnosis and ... European Heart Journal (1) and on ... recommendations were published in 2001 but they were restricted ...
(Date:8/30/2014)... Saturday 30 August 2014: A new sudden ... identifies candidates for implantable cardioverter defibrillators (ICDs) in ... ESC Congress by Task Force Chairperson Professor Perry ... Diagnosis and Management of Hypertrophic Cardiomyopathy" are published ... (1) and on the ESC Website. Previous ...
(Date:8/29/2014)... Daily Gossip writes in its review that this is actually ... method promises to teach readers how to eliminate the need ... sources for the production of energy. , Some of ... power. , The Home Made Energy review indicates that ... this is an online guide that will teach its users ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Indosoft, ... center software, announces the release of its most advanced ... a number of new features as well as updates ... software. , Q-Suite functionality on the presentation side ... TinyMCE into the script builder. This WYSIWYG ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 AGH Healthy ... the Doctors in Delaware at Atlantic General ... free health-related services. In addition to no-cost blood pressure ... offers first aid care at local sports tournaments. ... other medical staff provide free disease management and falls ...
Breaking Medicine News(10 mins):Health News:First comprehensive ESC Guidelines on aortic diseases published 2Health News:First comprehensive ESC Guidelines on aortic diseases published 3Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Indosoft Releases Q-Suite 5.7.7 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... , , WASHINGTON , Jan. ... which shows small businesses continue to struggle under the lagging economy ... decreases in revenue over the past 12 months rose to its ... to get adequate financing for their business. Despite a very dismal ...
... ... charter flight from JFK to Port-au-Prince to bring doctors and relief workers to help ... ... flight organized by the Church of Scientology carried 126 doctors, nurses, emergency medical technicians ...
... , Jan. 19 A shipment of Lutheran World ... Windsor, Md. , today, to be distributed to Haitian earthquake survivors. ... of 650 health kits and 1500 layettes, the first of multiple ... valued at nearly $500,000 and plans to send more ...
... , , PELLA, Iowa , Jan. 19 ... help those in the design, building and remodeling industries build their business ... will spring into action Feb. 2 through May 13 as ... cities. During the free events, attendees can obtain continuing education credits, learn ...
... Kris Freeman hopes for first U.S. cross-country medal since 1976; health ... Kris Freeman is back in the hunt for an ... ski team following a disappointing finish at the 2006 Games in Torino, ... at the 2010 Games in February, suffers from type 1 diabetes, a form ...
... at the University of California, San Diego School of Medicine ... which gliomas, a deadly type of brain tumor, can evade ... growth factor receptor (EGFR),that is crucial for tumor growth. In ... mutation is important not only to initiate the tumor, but ...
Cached Medicine News:Health News:NSBA 2009 Year-End Economic Report: Small Businesses Still Struggling 2Health News:NSBA 2009 Year-End Economic Report: Small Businesses Still Struggling 3Health News:Scientology-Sponsored Charter Flight Brings Medical and Spiritual Aid to Haiti 2Health News:Lutheran World Relief Health Kits, Layettes Enroute to Haiti; More Quilts and Kits Needed 2Health News:Lutheran World Relief Health Kits, Layettes Enroute to Haiti; More Quilts and Kits Needed 3Health News:Register Now for The Pro Expo(TM) Presented by Pella 2Health News:Register Now for The Pro Expo(TM) Presented by Pella 3Health News:In a Cross-Country Comeback, Skier With Type 1 Diabetes Named to U.S. Olympic Team 2Health News:In a Cross-Country Comeback, Skier With Type 1 Diabetes Named to U.S. Olympic Team 3Health News:In a Cross-Country Comeback, Skier With Type 1 Diabetes Named to U.S. Olympic Team 4Health News:Scientists show how brain tumors outsmart drugs 2